Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2008-03-11
2008-03-11
Helms, Larry R. (Department: 1643)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C530S387300, C530S388850, C435S069700
Reexamination Certificate
active
11024877
ABSTRACT:
The present invention relates to a method for stabilizing chimeric immunoglobulins or immunoglobulin fragments. Furthermore, the invention also provides a stabilized anti-EGP-2 scFv fragment.
REFERENCES:
patent: 2005/0136049 (2005-06-01), Ledbetter et al.
patent: WO 2004096271 (2004-11-01), None
Stratagen Catalog (1988) (pp. 1-2).
Jain (Scientific American Jul. 1994).
Chatterjee et al (Cancer Immunol. Imunother., 1994).
Dermer Biotechnology 12: 320, 1994.
Gura et al (Science vol. 278 Nov. 1997 1041-1042).
Seaver (1994; Genetic Engineering vol. 14(14):pp. 10 and 21.
Bissan Al-Lazikani et al., “Standard Conformations for the Canonical Structures of Immunoglobulins”, J. Mol. Biol., 1997, p. 927-948, vol. 273, Academic Press Limited.
Hendrick Bothmann et al., “Selection for a periplasmic factor improving phage display and functional periplasmic expression”, Nature Biotechnology, Apr. 1998, pp. 376-380, vol. 16.
Paul Carter et al., “Engineering antibodies for imaging and therapy”, Protein Engineering, pp. 449-454.
Paul Carter et al., “Humanization of an anti-p185HER2antibody for human cancer therapy”, Proc. Natl. Acad. Sci. USA, May 1992, pp. 4285-4289, vol. 89, Immunology.
Charles Eigenbrot et al., “X-ray Structures of the Antigen-binding Domains from Three Variants of Humanized anti-185HER2Antibody 4D5 and Comparison with Molecular Modeling”, J. Mol. Biol., 1993, pp. 969-995, vol. 229, Academic Press Limited.
Rudi Glockshuber et al., “A Comparison of Strategies to Stabilize Immunoglobulin Fv-Fragments”, Biochemistry, 1990, pp. 1362-1367, vol. 29, No. 6, American Chemical Society.
Wijnand Helfrich et al., “Construction and Characterization of a Bispecific Diabody for Retargeting T Cells to Human Carcinomas”, Int. J. Cancer, 1998, pp. 232-239, vol. 76, Wiley-Liss, Inc.
Sabine Jung et al., “Improving in vivo folding and stability of a single-chain Fv antibody fragment by loop grafting”, Protein Engineering, 1997, pp. 959-966, vol. 10, No. 8, Oxford University Press.
Achim Knappik et al., “Engineered turns of a recombinant antibody improve its in vivo folding”, Protein Engineering, Jan. 1995, pp. 81-89, No. 1.
Annette C. Langedijk et al., “The Nature of Antibody Heavy Chain Residue H6 Strongly Influences the Stability of a VHDomain Lacking the Disulfide Bridge”, J. Mol. Biol., 1998, pp. 95-110, vol. 283, Academic Press.
Andreas Plückthun et al., “New protein engineering approaches to multivalent and bispecific antibody fragments”, Immunotechnology, 1997, pp. 83-105, vol. 3, Elsevier.
Karl Proba et al., “Antibody scFv Fragments Without Disulfide Bonds Made by Molecular Evolution”, J. Mol. Biol., 1998, pp. 245-253, vol. 275, Academic Press Limited.
Frederick A. Saul et al., “Structural Patterns at Residue Positions 9, 18, 67 and 82 in the VHFramework Regions of Human and Murine Immunoglobulins”, J. Mol. Biol., 1993, pp. 15-20, vol. 230, Academic Press Limited.
Arne Wörn et al., “An intrinsically stable antibody scFv fragment can tolerate the loss of both disulfide bonds and fold correctly”, FEBS Letters, 1998, pp. 357-361, vol. 427, Federation of European Biochemical Societies.
Gibson et al., Proteins 3:155-60, 1988.
Knappik et al., Protein Engineering 8:81-89, 1995.
Saul et al., J. Mol. Biol. 230:15-20, 1993.
Paul Carter et al., “Engineering antibodies for imaging and therapy”, Protein Engineering, pp. 449-454, vol. 8 Current Op. Biotech (1997).
Honegger Annemarie
Pluckthun Andreas
Willuda Joerg
Bristol Lynn
Dann Dorfman Herrell & Skillman P.C.
Helms Larry R.
Rigaut Kathleen D.
University of Zurich
LandOfFree
Method for the stabilization of chimeric immunoglobulins or... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for the stabilization of chimeric immunoglobulins or..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for the stabilization of chimeric immunoglobulins or... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3933575